HomeMarket NewsMicro Cap StocksImunon Presents Encouraging Early Data on IMNN-001 in Ovarian Cancer

Imunon Presents Encouraging Early Data on IMNN-001 in Ovarian Cancer

Actionable Trade Ideas

always free


Imunon Inc (NASDAQ: IMNN) has released interim data from its Phase 1/2 OVATION 2 Study, presenting promising results for IMNN-001 in combination with neoadjuvant chemotherapy (NACT). The study focuses on newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Interim Progression-Free Survival and Overall Survival Data

The interim data from the intent-to-treat (ITT) population shows a significant delay in disease progression in the treatment arm compared to the control arm, with approximately 33% improvement. Furthermore, preliminary overall survival (OS) data indicates an approximate 9-month improvement in the treatment arm over the control arm.

Improved Outcomes with IMNN-001 and PARP Inhibitors

Subgroup analyses demonstrate that patients treated with a PARP inhibitor (PARPi) as maintenance therapy had longer progression-free survival (PFS) and overall survival (OS) when also treated with IMNN-001, compared to patients treated with NACT alone. The median PFS for the PARPi + NACT + IMNN-001 group was 23.7 months, compared to 15.7 months for the PARPi + NACT group. Additionally, the median OS has not yet been reached in the PARPi + NACT + IMNN-001 group, while it was 45.6 months in the PARPi + NACT group.

Positive Secondary Endpoints and Safety Profile

IMUNON also observed positive outcomes in other secondary endpoints. The treatment arm showed a higher R0 tumor resection score, with approximately 20% improvement compared to the control arm. Additionally, the chemotherapy response score (CRS 3) doubled to approximately 30% in the treatment arm, compared to 14% in the control arm. Safety analyses revealed good tolerability of IMNN-001 in this setting.

Final Study Readout and Market Reaction

The final readout for the OVATION 2 Study is expected by mid-2024. Following the announcement of the interim data, IMNN shares experienced a 6.62% decrease and were trading at $0.95 at the time of reporting.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.